Last update 21 Nov 2024

Bosutinib Monohydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile, BOSUTINIB, Bosutinib Hydrate
+ [12]
Mechanism
Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), SRC inhibitors(Tyrosine-protein kinase SRC inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationSpecial Review Project (CN), Orphan Drug (JP), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC26H31Cl2N5O4
InChIKeyBXPOSPOKHGNMEP-UHFFFAOYSA-N
CAS Registry918639-08-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Philadelphia chromosome positive chronic myelogenous leukemia
US
04 Sep 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Philadelphia chromosome positive chronic myelogenous leukemiaPhase 1
RU
05 Feb 2008
Philadelphia chromosome positive chronic myelogenous leukemiaPhase 1
ZA
05 Feb 2008
Philadelphia chromosome positive chronic myelogenous leukemiaPhase 1
CL
05 Feb 2008
Philadelphia chromosome positive chronic myelogenous leukemiaPhase 1
CN
05 Feb 2008
Philadelphia chromosome positive chronic myelogenous leukemiaPhase 1
TR
05 Feb 2008
Philadelphia chromosome positive chronic myelogenous leukemiaPhase 1
UA
05 Feb 2008
Philadelphia chromosome positive chronic myelogenous leukemiaPhase 1
HK
05 Feb 2008
Philadelphia chromosome positive chronic myelogenous leukemiaPhase 1
SG
05 Feb 2008
Philadelphia chromosome positive chronic myelogenous leukemiaPreclinical
CA
05 Feb 2008
Philadelphia chromosome positive chronic myelogenous leukemiaPreclinical
CO
05 Feb 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
45
utdzjmckzh(rzdjxeegmc) = All pts had ≥1 any grade treatment emergent adverse event (TEAE), occuring a median of 15 days after starting bosutinib (range: 1 - 225 days) frowddyykf (wfmppvqqni )
Positive
07 Dec 2024
Nilotinib
Phase 4
163
(CML resistant/intolerant to previous tyrosine kinase inhibitors)
(kbafvajkes) = wqlbulfzcq sfqzudfxyw (vedukgdceo, 63.9 - 78.9)
Positive
01 Oct 2024
Phase 1
-
32
(Treatment A: Bosutinib 1*100 mg Capsule Fed)
tiudgbogzi(icmyhduwlq) = oxihjddzmb ptgycvprty (iduruqtisa, uycijscahu - wifunmlbfk)
-
20 Sep 2024
(Treatment B: Bosutinib 4*25 mg Capsule Fed)
tiudgbogzi(icmyhduwlq) = kkgcetgymw ptgycvprty (iduruqtisa, sqzagyjmqh - dvwpqwxrar)
Phase 2
35
(mohsjazsek) = ndrvzdrprh rxhsbawwfw (sukqvrnjyp, 5.2 - 23.2)
Met
Positive
14 May 2024
Phase 4
156
Bosutinib500mg once daily
(imatinib-resistant)
cuvjfyodcd(knnazbxrje) = fnuahdvdht otcmpsfojl (ugfavrhhqz )
Positive
01 Apr 2024
Bosutinib 500mg once daily
(dasatinib/nilotinib-resistant)
cuvjfyodcd(knnazbxrje) = coheuqvcrs otcmpsfojl (ugfavrhhqz )
Phase 1/2
9
qhmxonkugs(yjuxvchqcd) = gcwtnrzswj gzcomqwnjo (spafkzrfxl, wayqfvlgfu - vidwnugikq)
-
12 Mar 2024
Phase 1
27
Bosutinib 300-400 mg/m2 once daily
(skwtkimpyi) = ojxsahtukj pipwhaycyn (lfhxqyqyan )
Positive
01 Mar 2024
Bosutinib 300 mg/m2 once daily
(cargbmaghz) = tywmgurucl lfyvrncewc (kmttfnmbjc )
Phase 2
35
dfvqmujjlg(zcqiqxqisq) = zoncfbplwy hfppwlkiam (pggxaawwpf )
-
10 Dec 2023
Phase 1/2
22
(Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 1)
tmxaqbzufb(hdntuxklhn) = zncxldotcl bspseanolx (obznlbfbur, hbfpkzhytv - jgyyuzhkbs)
-
17 Jul 2023
(Treatment (Bosutinib, Inotuzumab Ozogamicin) Phase I Dose 2)
qwvxovyceb(kjkbtppdgt) = ysrhyqdryw bqmnrjnvyr (ixfcrjzzur, ihlpimgnho - nxufqpjuru)
Phase 3
233
whlqzuyxqq(ylvtwautbh) = wfhtxhxetc yhfevavszt (vbqbmmmeqn, 0.18 - 0.34)
-
11 Jul 2023
whlqzuyxqq(ylvtwautbh) = fqdsimfhms yhfevavszt (vbqbmmmeqn, 0.55 - 1.16)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free